Lunan Pharmaceutical Group Corporation

Linyi, China

Lunan Pharmaceutical Group Corporation

Linyi, China
SEARCH FILTERS
Time filter
Source Type

Shu-Yong P.,Lunan Pharmaceutical Group Ltd Company
Chinese Journal of Antibiotics | Year: 2012

Objective: To optimize the culture medium and improve the yield of daunorubicin fermentation. Methods: Plackett-Burman designed for the most influencing factors detemination, the path of steepest ascent for the center test point determination, the Box-Behnken designed for the response surface analysis, experimented by shaking flask for fermentation. SAS software for analysis. Results: The three factors that selected by Plackett-Burman method were zein(A), FeSO4·7H2O(B) and NaCl(C). The result show that the mathematical modal for daunorubicin production is: Y= -16.09+13.55A+231.49B+5.20C-3.59A2+130.00AB -30774B2 -0.37AC+102.50BC-1.84C2. Based on the models, the optimum medium for daunorubicin production is zein 2.0%, FeSO4·7H2O 0.01%, NaCl 1.51%, Improved the daunorubicin production in 1500L pilot fermentor by 24%. Conclusion: Response surface analysis is able to overcome some drawbacks of the single factor experiment, and can use less experiment times on the experiment conducted a comprehensive study. Response surface analysis is a good combination for improving daunorubicin fermentation yield.


Sun C.,Jinan University | Sun C.,Lunan Pharmaceutical Group Corporation | Lai X.,Jinan University | Huang X.,Jinan University | Zeng Y.,Jinan University
Biological and Pharmaceutical Bulletin | Year: 2014

Ginsenoside Rg1 (Rg1), one of the active ingredients in Panax ginseng, has been known to regulate many cellular processes. The purpose of this study was to investigate the protective effects of Rg1 on apoptosis in mouse cultured astrocytes in vitro and a mouse model of cerebral ischemia and reperfusion in vivo. The cell apoptosis was measured by fluorescence microplate reader and xCELLigence system and the Ca2+ overload was recorded by confocal microscopy. The mitochondrial membrane potential and reactive oxygen species (ROS) were determined by flow cytometry. BALB/c mice were subjected to transient middle cerebral artery occlusion (MCAO) and randomly divided into four groups: Sham (sham-operated +0.9% saline), MCAO (MCAO+0.9% saline), Rg1-L (MCAO+Rg1 20 mg/kg) and Rg1-H (MCAO+Rg1 40 mg/kg). Neurological deficit scores, brain water content and infarct volume were evaluated at 24 h after reperfusion. The results showed that Rg1 significantly attenuated H2O2-induced apoptosis in astrocytes. Rg1 efficiently inhibited intracellular Ca2+ overload, loss of mitochondrial membrane potential, and ROS production in astrocytes. In vivo study, it was also observed that Rg1 markedly reduced the neurological deficit scores, brain edema, and infarct volume in the model mice. These results suggest that Rg1 possesses significant neuroprotective effects, which might be related to the prevention of astrocytes from apoptosis. © 2014 The Pharmaceutical Society of Japan.


Sun Z.X.,Lunan Pharmaceutical Group Co.
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials | Year: 2012

To optimize the technological parameters of the purification process for total organic acid and chlorogenic acid in Herba Artemisiae scopariae with macroporous adsorption resin. Static and dynamic adsorption-desorption methods were adopted to choose the optimal type of resin. Then orthogonal design L9 (3(4)) and single factor experiment were used to select the optimum purification process conditions. The optimal purification process for total organic acid and chlorogenic acid with HPD200A macroporous adsorption resin were as follows: the diameter height ratio of the resin was 1:6, the sample concentration was 1 g/mL, the absorption velocity was 1 BV/h (1 BV represented one column volume), the ratio of sample to HPD200A macroporous adsorption resin was 1.5:1 (W/W), 3 BV of water was used as purificant and 2 BV of 90% ethanol was used as eluant. Under these conditions, the purity of total organic acid and chlorogenic acid was 588.74% and 567.89%, respectively. The established purification process for total organic acid and chlorogenic acid in Herba Artemisiae scopariae with HPD200A macroporous adsorption resin is simple and stable and can be used in industrial production.


Patent
Lunan Pharmaceutical Group Corporation | Date: 2011-06-08

The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) amlodipine or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof, and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical composition in preparing a medicament for treating hypertension or metabolic syndrome. The pharmaceutical composition of the present invention can treat hypertension or metabolic syndrome, while effectively controlling the incidence of associated cardiovascular diseases and more potently improving survival prognosis in hypertensive patients. When blood pressure is lowered to desired level, the risk factors such as cardiovascular diseases are rectified, metabolic disorders and prognosis of patients are improved, and survival rate of hypertensive patients is raised.


Patent
Lunan Pharmaceutical Group Corporation | Date: 2011-04-13

The present invention provides a method of synthesizing sevoflurane, which comprises the following steps: taking hexafluoro isopropanol as the starting material and reacting it with trioxymethylene (or paraformaldehyde) in the presence of acid to generate dihexafluoro isopropanol formal derivatives, adding anhydrous aluminum trihalide to generate halomethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether, then reacting the halomethyl compound with metal fluoride to form the sevoflurane. The method is of low cost, and the reaction condition is easy to implement, and produces sevoflurane in large scale.


Patent
Lunan Pharmaceutical Group Corporation | Date: 2014-10-20

The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.


Patent
Lunan Pharmaceutical Group Corporation | Date: 2011-05-18

The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof; and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical composition in preparing a medicament for treating hypertension or metabolic syndrome. The pharmaceutical composition of the present invention can treat hypertension or metabolic syndrome, while effectively controlling the incidence of associated cardiovascular diseases and more potently improving survival prognosis in hypertensive patients. When blood pressure is lowered to desired level, the risk factors such as cardiovascular diseases are rectified, metabolic disorders and prognosis of patients are improved, and survival rate of hypertensive patients is raised.


Patent
Lunan Pharmaceutical Group Corporation | Date: 2011-05-25

The present invention provides the prasugrel bisulfate of formula (II) and pharmaceutical composition and use thereof. Prasugrel bisulfate of the present invention has good stability, oral absorbability, metabolic activity and platelet aggregation inhibition effect, and low toxicity, and is therefore a promising anticoagulant for preventing or treating diseases associated with thrombosis or embolism.


Provided are applications of arctigenin in formulating medicines for preventing or treating diseases related to blood cell reduction, and preparations that contain arctigenin, particularly micro-emulsions that contain arctigenin. Experiments show that arctigenin can significantly increase the white cell counts after chemotherapy, especially the neutrophil granulocyte counts.


Patent
Lunan Pharmaceutical Group Corporation | Date: 2016-08-31

The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.

Loading Lunan Pharmaceutical Group Corporation collaborators
Loading Lunan Pharmaceutical Group Corporation collaborators